Literature DB >> 35551464

Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.

Nicole M Myer1, Kohei Shitara2, Hyun C Chung3, Florian Lordick4, Ronan J Kelly5, Zsolt Szabo6, Z Alexander Cao7, Stephen Leong8, David H Ilson9, Wilko Weichert10.   

Abstract

Despite new therapeutic options, advanced gastric cancer remains associated with a poor prognosis compared with other cancers. Recent gains in the treatment of gastric cancer were accompanied by the identification of novel biomarkers associated with various cellular pathways and corresponding diagnostic technologies. It is expected that the standardization of clinical workflow and technological refinements in biomarker assessment will support greater personalization and further improve treatment outcomes. In this article, we review the current state of prognostic and predictive biomarkers in gastric cancer.
© 2022. Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates under exclusive license to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Gastric cancer; Microsatellite instability; Programmed death ligand 1; Tumor mutational burden

Mesh：

Substances：

Year:  2022        PMID： 35551464     DOI： 10.1007/s00432-021-03902-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.322


  105 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Authors:  Angela N Bartley; Mary Kay Washington; Nofisat Ismaila; Jaffer A Ajani
Journal:  J Oncol Pract       Date:  2016-11-29       Impact factor: 3.840

3.  Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

Authors:  Maria D Begnami; Emy Fukuda; José H T G Fregnani; Suely Nonogaki; André L Montagnini; Wilson L da Costa; Fernando A Soares
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

4.  Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry.

Authors:  A Arnold; S Daum; M von Winterfeld; E Berg; M Hummel; D Horst; B Rau; U Stein; C Treese
Journal:  Pathol Res Pract       Date:  2019-09-19       Impact factor: 3.250

5.  Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach.

Authors:  Tomio Arai; Urara Sakurai; Motoji Sawabe; Naoko Honma; Junko Aida; Yasuko Ushio; Nobuo Kanazawa; Kojiro Kuroiwa; Kaiyo Takubo
Journal:  Gastric Cancer       Date:  2012-12-29       Impact factor: 7.370

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 7.  HER2 testing in gastric cancer: An update.

Authors:  Lucas Faria Abrahao-Machado; Cristovam Scapulatempo-Neto
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

8.  Landscape of Microsatellite Instability Across 39 Cancer Types.

Authors:  Russell Bonneville; Melanie A Krook; Esko A Kautto; Jharna Miya; Michele R Wing; Hui-Zi Chen; Julie W Reeser; Lianbo Yu; Sameek Roychowdhury
Journal:  JCO Precis Oncol       Date:  2017-10-03

9.  Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).

Authors:  N Boku; M-H Ryu; K Kato; H C Chung; K Minashi; K-W Lee; H Cho; W K Kang; Y Komatsu; M Tsuda; K Yamaguchi; H Hara; S Fumita; M Azuma; L-T Chen; Y-K Kang
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976
View more
  1 in total

Review 1.  Adenosine signaling: Optimal target for gastric cancer immunotherapy.

Authors:  Junqing Wang; Linyong Du; Xiangjian Chen
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.